<?xml version='1.0' encoding='utf-8'?>
<document id="23061428"><sentence text="Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin."><entity charOffset="11-19" id="DDI-PubMed.23061428.s1.e0" text="rifampin" /><entity charOffset="24-38" id="DDI-PubMed.23061428.s1.e1" text="mefenamic acid" /><entity charOffset="87-100" id="DDI-PubMed.23061428.s1.e2" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.23061428.s1.e0" e2="DDI-PubMed.23061428.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s1.e0" e2="DDI-PubMed.23061428.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s1.e0" e2="DDI-PubMed.23061428.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s1.e1" e2="DDI-PubMed.23061428.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s1.e1" e2="DDI-PubMed.23061428.s1.e2" /></sentence><sentence text="Dapagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that decreases serum glucose by reducing renal glucose reabsorption, thereby promoting urinary glucose excretion"><entity charOffset="0-13" id="DDI-PubMed.23061428.s2.e0" text="Dapagliflozin" /><entity charOffset="29-43" id="DDI-PubMed.23061428.s2.e1" text="sodium glucose" /><entity charOffset="99-106" id="DDI-PubMed.23061428.s2.e2" text="glucose" /><entity charOffset="125-132" id="DDI-PubMed.23061428.s2.e3" text="glucose" /><entity charOffset="173-180" id="DDI-PubMed.23061428.s2.e4" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e0" e2="DDI-PubMed.23061428.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e0" e2="DDI-PubMed.23061428.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e0" e2="DDI-PubMed.23061428.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e0" e2="DDI-PubMed.23061428.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e0" e2="DDI-PubMed.23061428.s2.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e1" e2="DDI-PubMed.23061428.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e1" e2="DDI-PubMed.23061428.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e1" e2="DDI-PubMed.23061428.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e1" e2="DDI-PubMed.23061428.s2.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e2" e2="DDI-PubMed.23061428.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e2" e2="DDI-PubMed.23061428.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e2" e2="DDI-PubMed.23061428.s2.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e3" e2="DDI-PubMed.23061428.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s2.e3" e2="DDI-PubMed.23061428.s2.e4" /></sentence><sentence text=" Dapagliflozin is primarily metabolized via the uridine diphosphate-glucuronosyltransferase (UGT)1A9 pathway to its major inactive metabolite, dapagliflozin 3-O-glucuronide"><entity charOffset="1-14" id="DDI-PubMed.23061428.s3.e0" text="Dapagliflozin" /><entity charOffset="48-67" id="DDI-PubMed.23061428.s3.e1" text="uridine diphosphate" /><entity charOffset="143-172" id="DDI-PubMed.23061428.s3.e2" text="dapagliflozin 3-O-glucuronide" /><pair ddi="false" e1="DDI-PubMed.23061428.s3.e0" e2="DDI-PubMed.23061428.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s3.e0" e2="DDI-PubMed.23061428.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s3.e0" e2="DDI-PubMed.23061428.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s3.e1" e2="DDI-PubMed.23061428.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s3.e1" e2="DDI-PubMed.23061428.s3.e2" /></sentence><sentence text=" The aim of this study was to evaluate the potential for drug-drug interaction between dapagliflozin and two potential UGT1A9 modulators"><entity charOffset="87-100" id="DDI-PubMed.23061428.s4.e0" text="dapagliflozin" /></sentence><sentence text="" /><sentence text="The results of two open-label, non-randomized, single-sequence studies are reported in which the effects of rifampin (a pleiotropic drug-metabolizing enzyme inducer; study 1) and mefenamic acid (a strong UGT1A9 inhibitor; study 2) were evaluated on the pharmacokinetics and pharmacodynamics (assessed by urinary glucose excretion [UGE]) of dapagliflozin in healthy subjects"><entity charOffset="108-116" id="DDI-PubMed.23061428.s6.e0" text="rifampin" /><entity charOffset="179-193" id="DDI-PubMed.23061428.s6.e1" text="mefenamic acid" /><entity charOffset="312-319" id="DDI-PubMed.23061428.s6.e2" text="glucose" /><entity charOffset="340-353" id="DDI-PubMed.23061428.s6.e3" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e0" e2="DDI-PubMed.23061428.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e0" e2="DDI-PubMed.23061428.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e0" e2="DDI-PubMed.23061428.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e0" e2="DDI-PubMed.23061428.s6.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e1" e2="DDI-PubMed.23061428.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e1" e2="DDI-PubMed.23061428.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e1" e2="DDI-PubMed.23061428.s6.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e2" e2="DDI-PubMed.23061428.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s6.e2" e2="DDI-PubMed.23061428.s6.e3" /></sentence><sentence text=" In study 1, 14 subjects received single doses of dapagliflozin 10 mg alone and in the presence of rifampin 600 mg QD (6 days)"><entity charOffset="50-63" id="DDI-PubMed.23061428.s7.e0" text="dapagliflozin" /><entity charOffset="99-107" id="DDI-PubMed.23061428.s7.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.23061428.s7.e0" e2="DDI-PubMed.23061428.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s7.e0" e2="DDI-PubMed.23061428.s7.e1" /></sentence><sentence text=" In study 2, 16 subjects received single doses of dapagliflozin 10 mg alone and in the presence of mefenamic acid 250 mg q6h (5 days)"><entity charOffset="50-63" id="DDI-PubMed.23061428.s8.e0" text="dapagliflozin" /><entity charOffset="99-113" id="DDI-PubMed.23061428.s8.e1" text="mefenamic acid" /><pair ddi="false" e1="DDI-PubMed.23061428.s8.e0" e2="DDI-PubMed.23061428.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s8.e0" e2="DDI-PubMed.23061428.s8.e1" /></sentence><sentence text="" /><sentence text="Rifampin reduced total exposure (area under the concentration-time curve from time 0 to infinity [AUC0-inf]) to dapagliflozin by 22% and mefenamic acid increased dapagliflozin AUC0-inf by 51%"><entity charOffset="0-8" id="DDI-PubMed.23061428.s10.e0" text="Rifampin" /><entity charOffset="112-125" id="DDI-PubMed.23061428.s10.e1" text="dapagliflozin" /><entity charOffset="137-151" id="DDI-PubMed.23061428.s10.e2" text="mefenamic acid" /><entity charOffset="162-175" id="DDI-PubMed.23061428.s10.e3" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e0" e2="DDI-PubMed.23061428.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e0" e2="DDI-PubMed.23061428.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e0" e2="DDI-PubMed.23061428.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e0" e2="DDI-PubMed.23061428.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e1" e2="DDI-PubMed.23061428.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e1" e2="DDI-PubMed.23061428.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e1" e2="DDI-PubMed.23061428.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e2" e2="DDI-PubMed.23061428.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s10.e2" e2="DDI-PubMed.23061428.s10.e3" /></sentence><sentence text=" No clinically meaningful effect of rifampin or mefenamic acid on the pharmacokinetics of dapagliflozin or on dapagliflozin-mediated urinary glucose excretion was observed"><entity charOffset="36-44" id="DDI-PubMed.23061428.s11.e0" text="rifampin" /><entity charOffset="48-62" id="DDI-PubMed.23061428.s11.e1" text="mefenamic acid" /><entity charOffset="90-103" id="DDI-PubMed.23061428.s11.e2" text="dapagliflozin" /><entity charOffset="110-123" id="DDI-PubMed.23061428.s11.e3" text="dapagliflozin" /><entity charOffset="141-148" id="DDI-PubMed.23061428.s11.e4" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e0" e2="DDI-PubMed.23061428.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e0" e2="DDI-PubMed.23061428.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e0" e2="DDI-PubMed.23061428.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e0" e2="DDI-PubMed.23061428.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e0" e2="DDI-PubMed.23061428.s11.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e1" e2="DDI-PubMed.23061428.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e1" e2="DDI-PubMed.23061428.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e1" e2="DDI-PubMed.23061428.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e1" e2="DDI-PubMed.23061428.s11.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e2" e2="DDI-PubMed.23061428.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e2" e2="DDI-PubMed.23061428.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e2" e2="DDI-PubMed.23061428.s11.e4" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e3" e2="DDI-PubMed.23061428.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23061428.s11.e3" e2="DDI-PubMed.23061428.s11.e4" /></sentence><sentence text="" /><sentence text="Modest changes in dapagliflozin exposure were seen with rifampin and mefenamic acid with minor changes in UGE, none of which were considered clinically meaningful"><entity charOffset="18-31" id="DDI-PubMed.23061428.s13.e0" text="dapagliflozin" /><entity charOffset="56-64" id="DDI-PubMed.23061428.s13.e1" text="rifampin" /><entity charOffset="69-83" id="DDI-PubMed.23061428.s13.e2" text="mefenamic acid" /><pair ddi="false" e1="DDI-PubMed.23061428.s13.e0" e2="DDI-PubMed.23061428.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23061428.s13.e0" e2="DDI-PubMed.23061428.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s13.e0" e2="DDI-PubMed.23061428.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23061428.s13.e1" e2="DDI-PubMed.23061428.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23061428.s13.e1" e2="DDI-PubMed.23061428.s13.e2" /></sentence><sentence text="" /></document>